摘要
目的探讨氟奋乃静联合氨磺必利治疗难治性精神分裂症的临床疗效及安全性。方法将2009年11月至2012年11月新乡医学院第二附属医院收治的85例难治性精神分裂症者按照随机数字表法分为两组：奥氮平组（42例）口服奥氮平5-10 mg/d,每日2次;联合组（43例）口服氟奋乃静4-8 mg/d＋氨磺必利400-800 mg/d,每日2次。采用阳性和阴性症状量表（PANSS）、临床总体印象量表（CGI）、功能大体评定量表（GAF）和不良反应量表（TESS）评定两组患者的临床疗效和不良反应情况。结果奥氮平组的有效率为59.5%,联合组为72.1%,两组疗效比较差异有统计学意义（P〈0.05）;联合组PANSS总分、阳性症状分、阴性症状分、精神病理分及CGI-SI总分均显著低于奥氮平组（P〈0.01）,而联合组GAF分高于奥氮平组（P〈0.01）。联合组的不良反应发生率及复发率显著低于奥氮平组（48.8%比57.1%,20.9%比31.0%）（P〈0.05或P〈0.01）。结论氟奋乃静联合氨磺必利治疗难治性精神分裂症的临床疗效显著,不良反应少,依从性好。
Objective To evaluate the therapeutic efficacy and adverse effects of fluphenazine combined with amisulpride in treating refractory schizophrenia.Methods A total of 85 patients with refractory schizophrenia admitted in the Second Affiliated Hospital of Xinxiang Medical University from Nov.2009 to Nov.2012 were randomly divided into combined treatment group（43 cases） and olanzapine group（42 cases） by the random number table method.Patients in olanzapine group orally took 5-10 mg/d of olanzapine,twice a day,while patients in combined treatment group orally took4-8 mg/d of fluphenazine combined with 400-800 mg/d of amisulpride,twice a day.Positive and negative syndrome scale（PANSS）,clinical global impression（CGI）,global assessment function（GAF） and treatment emergent symptoms scale（TESS） were used to evaluate the therapeutic efficacy and adverse effects.Results The marked effective rate of olanzapine group was 59.5%,that of the combined treatment group was 72.1%.There was statistically significant difference of the total effective rate between the two groups（P〈0.05）.Compare with the olanzapine group,scores of PANSS-G（general psychopathology scale）,PANSS-P（positive scale）,PANSS-T（total score）,as well as the CGI-SI scores of the combined treatment group were all lower,while GAF score was significantly increased（P〈0.01）.The incidence rate of adverse reaction and recurrence rate of the combined treatment group were significantly lower than those of the olanzapine group（48.8% vs 20.9%）,（57.1% vs 31.0%）（P〈0.05 or P〈0.01）.Conclusion Fluphenazine combined with amisulpride has good efficacy in treating refractory schizophrenia,with less side effects and good compliance.
出处
《医学综述》
2015年第7期1332-1334,共3页
Medical Recapitulate
